Krishna Institute of Medical Sciences Limited Share Price & Analysis
Price Chart
Fundamentals
Concerns
- ✗Premium to sector peers (P/E 136x vs industry 54.4x)
- ✗High premium to book value (P/B 13.3x)
- ✗Elevated debt levels (D/E 1.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
KIMS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 38.82% | 38.82% | 38.82% | 38.82% | 38.82% | 38.82% |
| FII | 15.27% | 16.73% | 17.84% | 15.85% | 15.68% | 15.44% |
| DII | 34.24% | 33.13% | 32.12% | 32.29% | 32.05% | 31.95% |
| Public | 11.67% | 11.32% | 11.22% | 13.03% | 13.45% | 13.78% |
Corporate Events
To consider and evaluate the proposal for raising of funds by way of issuance of one or more instrument(s) / securities which may include equity shares, fully convertible warrants and/or any other eligible securities (convertible / non-convertible) and /
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share
Latest News
All news →Krisha Institute gets nod to list ₹19.87M shares via QIP
*Krishna Institute of Medical Sciences gets SEBI approval for listing 1,98,67,549 shares issued via QIP.* The **19.87 million** equity shares of Rs. 2 each were allocated to qualified institutional buyers. This follows the recent qualified institutional placement aimed at raising capital. Listing these shares enhances liquidity and market visibility. 📊 *STOCKS:* KIMS | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #QIP
Krishna Institute reports FY26 audited financial results
*Krishna Institute reports FY26 audited financial results* with standalone and consolidated financial statements released. The filing provides key insights into the company’s performance for the year ended March 31, 2026. Traders will assess revenue, profit margins, and debt levels once figures are available. **No major deviation or surprise indicated** in the headline update. 📊 *STOCKS:* KIMS | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Earnings
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.1K Cr ▲7.7% | ₹998 Cr ▲3.9% | ₹961 Cr ▲10.2% | ₹872 Cr ▲9.4% | ₹797 Cr ▲3.2% | ₹772 Cr ▼0.6% | ₹777 Cr ▲12.9% | ₹688 Cr |
| Op. Profit | ₹206 Cr ▲3.5% | ₹199 Cr ▼2.5% | ₹204 Cr ▲5.7% | ₹193 Cr ▼2.5% | ₹198 Cr ▲5.9% | ₹187 Cr ▼14.2% | ₹218 Cr ▲21.8% | ₹179 Cr |
| OPM | 19.0% ▼5.0% | 20.0% ▼4.8% | 21.0% ▼4.5% | 22.0% ▼12.0% | 25.0% ▲4.2% | 24.0% ▼14.3% | 28.0% ▲7.7% | 26.0% |
| Net Profit | ₹33 Cr ▼36.5% | ₹52 Cr ▼27.8% | ₹72 Cr ▼15.3% | ₹85 Cr ▼19.8% | ₹106 Cr ▲15.2% | ₹92 Cr ▼24.0% | ₹121 Cr ▲27.4% | ₹95 Cr |
| EPS (₹) | 1.06 ▼20.3% | 1.33 ▼20.4% | 1.67 ▼14.8% | 1.96 ▼22.8% | 2.54 ▲14.4% | 2.22 ▼17.2% | 2.68 ▲24.1% | 2.16 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.9K Cr ▲28.7% | ₹3.0K Cr ▲21.5% | ₹2.5K Cr ▲13.6% | ₹2.2K Cr ▲33.1% | ₹1.7K Cr ▲24.1% | ₹1.3K Cr ▲18.4% | ₹1.1K Cr ▲22.3% | ₹918 Cr ▲38.3% | ₹664 Cr ▲17.1% | ₹567 Cr |
| Expenses | ₹3.1K Cr ▲38.4% | ₹2.2K Cr ▲21.2% | ₹1.9K Cr ▲16.6% | ₹1.6K Cr ▲40.9% | ₹1.1K Cr ▲18.2% | ₹953 Cr ▲9.3% | ₹872 Cr ▲4.7% | ₹833 Cr ▲40.5% | ₹593 Cr ▲31.8% | ₹450 Cr |
| Op. Profit | ₹802 Cr ▲1.1% | ₹793 Cr ▲22.4% | ₹648 Cr ▲6.1% | ₹611 Cr ▲16.6% | ₹524 Cr ▲39.0% | ₹377 Cr ▲50.2% | ₹251 Cr ▲195.3% | ₹85 Cr ▲19.7% | ₹71 Cr ▼39.8% | ₹118 Cr |
| OPM | 21.0% ▼19.2% | 26.0% ▲0.0% | 26.0% ▼7.1% | 28.0% ▼12.5% | 32.0% ▲14.3% | 28.0% ▲27.3% | 22.0% ▲144.4% | 9.0% ▼18.2% | 11.0% ▼47.6% | 21.0% |
| Other Income | ₹18 Cr ▼58.1% | ₹43 Cr ▲230.8% | ₹13 Cr ▼68.3% | ₹41 Cr ▲51.9% | ₹27 Cr ▲200.0% | ₹9 Cr ▲80.0% | ₹5 Cr ▼16.7% | ₹6 Cr ▼83.8% | ₹37 Cr ▲1133.3% | ₹3 Cr |
| Interest | ₹202 Cr ▲102.0% | ₹100 Cr ▲81.8% | ₹55 Cr ▲48.6% | ₹37 Cr ▲68.2% | ₹22 Cr ▼40.5% | ₹37 Cr ▼15.9% | ₹44 Cr ▼10.2% | ₹49 Cr ▼44.3% | ₹88 Cr ▲175.0% | ₹32 Cr |
| Depreciation | ₹283 Cr ▲59.9% | ₹177 Cr ▲20.4% | ₹147 Cr ▲14.0% | ₹129 Cr ▲76.7% | ₹73 Cr ▲4.3% | ₹70 Cr ▼1.4% | ₹71 Cr ▲26.8% | ₹56 Cr ▲40.0% | ₹40 Cr ▲14.3% | ₹35 Cr |
| PBT | ₹334 Cr ▼40.1% | ₹558 Cr ▲21.3% | ₹460 Cr ▼5.2% | ₹485 Cr ▲6.1% | ₹457 Cr ▲63.8% | ₹279 Cr ▲97.9% | ₹141 Cr ▲1040.0% | ₹-15 Cr ▲25.0% | ₹-20 Cr ▼137.7% | ₹53 Cr |
| Tax % | 28.0% ▲7.7% | 26.0% ▼3.7% | 27.0% ▲8.0% | 25.0% ▲0.0% | 25.0% ▼3.8% | 26.0% ▲44.4% | 18.0% ▼91.9% | 223.0% ▲77.0% | 126.0% ▲240.5% | 37.0% |
| Net Profit | ₹242 Cr ▼41.7% | ₹415 Cr ▲23.5% | ₹336 Cr ▼8.2% | ₹366 Cr ▲6.4% | ₹344 Cr ▲67.8% | ₹205 Cr ▲78.3% | ₹115 Cr ▲334.7% | ₹-49 Cr ▼6.5% | ₹-46 Cr ▼239.4% | ₹33 Cr |
| EPS (₹) | 6.03 ▼37.3% | 9.61 ▲24.0% | 7.75 ▼7.8% | 8.41 ▲1.1% | 8.32 ▲60.3% | 5.19 ▲62.2% | 3.2 ▲350.0% | -1.28 ▲3.0% | -1.32 ▼245.1% | 0.91 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹80 Cr ▲0.0% | ₹80 Cr ▲0.0% | ₹80 Cr ▲0.0% | ₹80 Cr ▲0.0% | ₹80 Cr ▲2.6% | ₹78 Cr ▲5.4% | ₹74 Cr ▲0.0% | ₹74 Cr ▲48.0% | ₹50 Cr ▼30.6% | ₹72 Cr |
| Reserves | ₹2.2K Cr ▲5.3% | ₹2.1K Cr ▲17.7% | ₹1.7K Cr ▲9.9% | ₹1.6K Cr ▲21.7% | ₹1.3K Cr ▲66.3% | ₹786 Cr ▲50.0% | ₹524 Cr ▲12.4% | ₹466 Cr ▲323.0% | ₹-209 Cr ▼182.0% | ₹255 Cr |
| Borrowings | ₹4.3K Cr ▲66.3% | ₹2.6K Cr ▲88.7% | ₹1.4K Cr ▲99.9% | ₹678 Cr ▲163.8% | ₹257 Cr ▼18.7% | ₹316 Cr ▼14.4% | ₹369 Cr ▲9.8% | ₹336 Cr ▼55.4% | ₹753 Cr ▲168.9% | ₹280 Cr |
| Other Liabilities | ₹1.3K Cr ▲26.4% | ₹995 Cr ▲56.4% | ₹636 Cr ▲15.0% | ₹553 Cr ▲112.7% | ₹260 Cr ▲2.8% | ₹253 Cr ▲11.0% | ₹228 Cr ▼3.8% | ₹237 Cr ▼34.0% | ₹359 Cr ▲115.0% | ₹167 Cr |
| Total Liabilities | ₹7.8K Cr ▲36.4% | ₹5.7K Cr ▲48.9% | ₹3.8K Cr ▲31.7% | ₹2.9K Cr ▲52.4% | ₹1.9K Cr ▲32.9% | ₹1.4K Cr ▲20.0% | ₹1.2K Cr ▲7.2% | ₹1.1K Cr ▲16.8% | ₹954 Cr ▲23.3% | ₹774 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹5.7K Cr ▲70.5% | ₹3.3K Cr ▲37.6% | ₹2.4K Cr ▲37.8% | ₹1.8K Cr ▲75.7% | ₹1.0K Cr ▲7.9% | ₹931 Cr ▲1.6% | ₹916 Cr ▲6.1% | ₹863 Cr ▲14.3% | ₹755 Cr ▲45.8% | ₹518 Cr |
| CWIP | ₹606 Cr ▼50.1% | ₹1.2K Cr ▲102.3% | ₹600 Cr ▲25.8% | ₹477 Cr ▲2171.4% | ₹21 Cr ▲133.3% | ₹9 Cr ▲350.0% | ₹2 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹64 Cr |
| Investments | ₹103 Cr ▲4.0% | ₹99 Cr ▼36.9% | ₹157 Cr ▲130.9% | ₹68 Cr ▼79.5% | ₹332 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹14 Cr |
| Other Assets | ₹1.3K Cr ▲30.3% | ₹1.0K Cr ▲63.4% | ₹629 Cr ▲6.6% | ₹590 Cr ▲8.1% | ₹546 Cr ▲10.8% | ₹493 Cr ▲78.6% | ₹276 Cr ▲10.4% | ₹250 Cr ▲25.6% | ₹199 Cr ▲12.4% | ₹177 Cr |
| Total Assets | ₹7.8K Cr ▲36.4% | ₹5.7K Cr ▲48.9% | ₹3.8K Cr ▲31.7% | ₹2.9K Cr ▲52.4% | ₹1.9K Cr ▲32.9% | ₹1.4K Cr ▲20.0% | ₹1.2K Cr ▲7.2% | ₹1.1K Cr ▲16.8% | ₹954 Cr ▲23.3% | ₹774 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹511 Cr ▼12.2% | ₹582 Cr ▲11.7% | ₹521 Cr ▲20.6% | ₹432 Cr ▲33.3% | ₹324 Cr ▼9.0% | ₹356 Cr ▲76.2% | ₹202 Cr ▲50.7% | ₹134 Cr ▲26.4% | ₹106 Cr ▲29.3% | ₹82 Cr |
| Investing CF | ₹-1.5K Cr ▼30.1% | ₹-1.1K Cr ▼48.2% | ₹-753 Cr ▼81.0% | ₹-416 Cr ▼1.0% | ₹-412 Cr ▼16.4% | ₹-354 Cr ▼183.2% | ₹-125 Cr ▼13.6% | ₹-110 Cr ▼71.9% | ₹-64 Cr ▲36.0% | ₹-100 Cr |
| Financing CF | ₹940 Cr ▲73.1% | ₹543 Cr ▲150.2% | ₹217 Cr ▲985.0% | ₹20 Cr ▼67.2% | ₹61 Cr ▲510.0% | ₹10 Cr ▲122.7% | ₹-44 Cr ▼63.0% | ₹-27 Cr ▲30.8% | ₹-39 Cr ▼262.5% | ₹24 Cr |
| Net Cash Flow | ₹-1 Cr ▼111.1% | ₹9 Cr ▲160.0% | ₹-15 Cr ▼141.7% | ₹36 Cr ▲238.5% | ₹-26 Cr ▼316.7% | ₹12 Cr ▼62.5% | ₹32 Cr ▲1166.7% | ₹-3 Cr ▼200.0% | ₹3 Cr ▼40.0% | ₹5 Cr |
| Free Cash Flow | ₹-902 Cr ▼137.4% | ₹-380 Cr ▼204.0% | ₹-125 Cr ▲10.7% | ₹-140 Cr ▼190.9% | ₹154 Cr ▼41.2% | ₹262 Cr ▲74.7% | ₹150 Cr ▲163.2% | ₹57 Cr ▲16.3% | ₹49 Cr ▲372.2% | ₹-18 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52d ▲8.3% | 48d ▲11.6% | 43d ▲2.4% | 42d ▲50.0% | 28d ▼6.7% | 30d ▼30.2% | 43d ▼12.2% | 49d ▼16.9% | 59d ▲0.0% | 59d |
| Inventory Days | 44d | — | — | — | 37d ▲23.3% | 30d ▼31.8% | 44d ▼6.4% | 47d ▲2.2% | 46d ▲7.0% | 43d |
| Days Payable | 146d | — | — | — | 133d ▼20.4% | 167d ▼5.6% | 177d ▼2.2% | 181d ▼15.8% | 215d ▲3.9% | 207d |
| Cash Conv. Cycle | -50d ▼204.2% | 48d ▲11.6% | 43d ▲2.4% | 42d ▲162.7% | -67d ▲36.8% | -106d ▼16.5% | -91d ▼7.1% | -85d ▲22.7% | -110d ▼4.8% | -105d |
| Working Capital Days | -35d ▼20.7% | -29d ▼480.0% | -5d ▼162.5% | 8d ▲366.7% | -3d ▲90.3% | -31d ▼106.7% | -15d ▲0.0% | -15d ▲95.5% | -333d ▼1380.8% | 26d |
| ROCE | 9.0% ▼40.0% | 15.0% ▼11.8% | 17.0% ▼29.2% | 24.0% ▼29.4% | 34.0% ▲17.2% | 29.0% ▲45.0% | 20.0% ▲300.0% | 5.0% ▼54.5% | 11.0% ▼26.7% | 15.0% |
Source: Screener.in · Lower days = better efficiency
About Krishna Institute of Medical Sciences Limited
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.
Healthcare · Healthcare Services